Other members of the consortium are: Prothix BV; Aristi Biotech BV; the University Medical Center Utrecht; and GenOnway.
The consortium is developing a novel treatment for clotting disorders, targeting anti-thrombin III, a protein that inhibits blood clotting. The novel antibody has the potential to both prevent and treat bleeding in patients with disorders such as haemophilia.
Neil Butt, vice president of Business Development at Abzena, said: "Applying our Composite Human Antibody technology to this novel product will help produce a less immunogenic version, giving it a greater chance of improving the lives of patients."
Antitope provides immunogenicity assessment, protein engineering to create humanised antibodies and de-immunised therapeutic proteins, and cell line development for manufacture.
The Eurostars Programme is a European joint programme dedicated to giving a leg-up to small-to-medium sized research & development companies.
Shares in Abzena were up 1.8% at 56p in morning trade.